ReviewInternational journal of hematology2010
Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia.
Review in International journal of hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell LymphomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Pooled it
- Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.Journal of hematology & oncology · 2018Article
- Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine.Molecular and clinical oncology · 2017Article
- Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.Internal medicine (Tokyo, Japan) · 2017Review
- Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia.Case reports in hematology · 2015Article
- Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Current opinion in oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cell lymphomas and leukemias are aggressive neoplasms. Clinically, they can be classified into nasal, non-nasal and lymphoma/leukemia subtypes. Treatment results are unfavorable. High-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) may improve patient outcome. For autologous HSCT, a critical review of the literature shows that most patients with nasal NK cell lymphoma in complete remission (CR) appear to do well without HSCT. However, patients with refractory diseases and untreated relapses have poor outcome with HSCT. Therefore, identification of patients with nasal NK cell lymphoma in CR who are at high risk of relapse may be necessary before autologous HSCT can be recommended. Patients with disseminated nasal NK cell lymphoma, non-nasal NK cell lymphoma and NK cell leukemia have poor outcome with autologous HSCT. Allogeneic HSCT may be beneficial to these patients. Most of the reported cases have been performed from HLA-identical sibling donors, and data on alternative HSC sources including matched unrelated donors and umbilical cord blood are very limited. Continuous efforts should be devoted to risk stratification for identifying high-risk individuals for HSCT, and defining the optimal conditioning regimen for NK cell lymphomas.
Indexed as
Identifiers
21107769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.